 For people who are not eligible for a stem cell transplant , immunotherapy with a combination of histamine dihydrochloride ( Ceplene ) and interleukin 2 ( Proleukin ) after the completion of consolidation has been shown to reduce the absolute relapse risk by 14 % , translating to a 50 % increase in the likelihood of maintained remission . 
 For people <a href='null_relcl' title='1'><mark>who</mark></a><a href='negative_concord' title='2'><mark>are</mark></a> <a href='negative_concord' title='3'><mark>not</mark></a>eligible for a stem cell transplant , immunotherapy with a combination of histamine dihydrochloride ( Ceplene ) and interleukin 2 ( Proleukin ) after the completion of consolidation <a href='been_done' title='4'><mark>has</mark></a> been shown to reduce the absolute relapse risk by 14 % , translating to a 50 % increase in the likelihood of maintained remission . 
For ppl ain't eligible fir a stem cell transplant , immunotherapy with a combination of histamine dihydrochloride ( Ceplene ) and interleukin 2 ( Proleukin ) after the completion of consolidation done been shown to reduce the absolute relapse risk by 14 % , translating to a 50 % increase in da likelihood of maintained remission .